Human Reproduction Update, Vol.5, No.5 pp.493-499, 1999
© European Society of Human Reproduction and Embryology 1999; all rights reserved
Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rational, results, reflections refinements
0 Fertility Unit, Lis Maternity Hospital, Sourasky Tel Aviv Medical Center, Tel Aviv, Israel 2 Ares-Serono, Geneva, Switzerland 1 Corresponding author address: 8 Kashani Street, Tel Aviv 69499, Israel
Abstract
Low-dose follicle stimulating hormone (FSH) regimens for induction of ovulation for women with polycystic ovaries have succeeded in reducing the rate of ovarian hyperstimulation syndrome (OHSS) almost to nil and the rate of multiple pregnancies to a minimum of 6%. This has been achieved by reaching, but not exceeding, the threshold level of FSH, starting with a daily dose of 75 IU for 14 days, using small incremental dose rises where necessary, and inducing uniovulation in 70% of cycles. Conception rates are as good, if not better, than those achieved with conventional therapy. The miscarriage rate is still relatively high (20-25%) and obese women fare worse. Serum oestradiol concentrations and the number of large and intermediate follicles on the day of human chorionic gonadotrophin administration are much lower, in parallel with lower serum FSH concentrations. Inhibin values increase with the rise in serum FSH concentrations but those of luteinizing hormone decrease steadily throughout the follicular phase. New data using recombinant hFSH (rhFSH), rather than urinary gonadotrophin as the ovarian stimulant, demonstrate that treatment time is shortened. However, the ideal regimen has still to be formulated.
Key words: follicle-stimulating hormone/low-dose regime/ovulation induction/polycystic ovary syndrome
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Nyboe Andersen, A. Balen, P. Platteau, P. Devroey, L. Helmgaard, J.-C. Arce, and for the Bravelle Ovulation Induction (BOI) Study G Predicting the FSH threshold dose in women with WHO Group II anovulatory infertility failing to ovulate or conceive on clomiphene citrate Hum. Reprod., June 1, 2008; 23(6): 1424 - 1430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Franks, J. Stark, and K. Hardy Follicle dynamics and anovulation in polycystic ovary syndrome Hum. Reprod. Update, May 22, 2008; (2008) dmn015v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consens Consensus on infertility treatment related to polycystic ovary syndrome Hum. Reprod., March 1, 2008; 23(3): 462 - 477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Balen, P. Platteau, A. N. Andersen, P. Devroey, L. Helmgaard, J.-C. Arce, and for the Bravelle Ovulation Induction (BOI) Study G Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomized controlled non-inferiority trial Hum. Reprod., July 1, 2007; 22(7): 1816 - 1823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Cedrin-Durnerin, N. Massin, J. Galey-Fontaine, H. Bry-Gauillard, M. Roger, N. Lahlou, and J.N. Hugues Timing of FSH administration for ovarian stimulation in normo-ovulatory women: comparison of an early or a mid follicular phase initiation of a short-term treatment Hum. Reprod., November 1, 2006; 21(11): 2941 - 2947. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.N. Hugues, I. Cedrin-Durnerin, C.M. Howles, and On Behalf of the Recombinant FSH OI Study Group The use of a decremental dose regimen in patients treated with a chronic low-dose step-up protocol for WHO Group II anovulation: a prospective randomized multicentre study Hum. Reprod., November 1, 2006; 21(11): 2817 - 2822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Platteau, A. N. Andersen, A. Balen, P. Devroey, P. Sorensen, L. Helmgaard, J.-C. Arce, and for the Menopur Ovulation Induction (MOI) Study Gr Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study Hum. Reprod., July 1, 2006; 21(7): 1798 - 1804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. E. Messinis Ovulation induction: a mini review Hum. Reprod., October 1, 2005; 20(10): 2688 - 2697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Homburg Clomiphene citrate--end of an era? a mini-review Hum. Reprod., August 1, 2005; 20(8): 2043 - 2051. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.N. Hugues, J. Soussis, I. Calderon, J. Balasch, R.A. Anderson, A. Romeu, and on behalf of the Recombinant LH Study Group Does the addition of recombinant LH in WHO group II anovulatory women over-responding to FSH treatment reduce the number of developing follicles? A dose-finding study Hum. Reprod., March 1, 2005; 20(3): 629 - 635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Bayram, M. van Wely, E. M Kaaijk, P. M M Bossuyt, and F. van der Veen Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial BMJ, January 24, 2004; 328(7433): 192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Christin-Maitre, J.N. Hugues, and on behalf of the Recombinant FSH Study Group A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome Hum. Reprod., August 1, 2003; 18(8): 1626 - 1631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. van Wely, N. Bayram, and F. van der Veen Recombinant FSH in alternative doses or versus urinary gonadotrophins for ovulation induction in subfertility associated with polycystic ovary syndrome: a systematic review based on a Cochrane review Hum. Reprod., June 1, 2003; 18(6): 1143 - 1149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Loumaye, P. Engrand, Z. Shoham, S. G. Hillier, D. T. Baird, and on behalf of the Recombinant LH Study Group Clinical evidence for an LH 'ceiling' effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation Hum. Reprod., February 1, 2003; 18(2): 314 - 322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Gokyar, A. Kokcu, F. Yanik, M. B. Cetinkaya, T. Alper, and E. Malatyalioglu Basal and day 12 inhibin concentrations in the prediction of ovarian response to gonadotrophins in women with PCOS Hum. Reprod., October 1, 2001; 16(10): 2079 - 2083. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Balasch, F. Fabregues, M. Creus, B. Puerto, J. Penarrubia, and J. A. Vanrell Follicular development and hormone concentrations following recombinant FSH administration for anovulation associated with polycystic ovarian syndrome: prospective, randomized comparison between low-dose step-up and modified step-down regimens Hum. Reprod., April 1, 2001; 16(4): 652 - 656. [Abstract] [Full Text] [PDF]
|
|